GLP‑1 therapies are evolving faster than any other drug class in the pharmacy benefit space, with new clinical indications, emerging safety considerations, and next‑generation competitors like recently-released Foundayo reshaping the landscape for employers. As utilization accelerates and pipeline products expand, plan sponsors face increasing pressure to balance evidence‑based access with high costs and operational complexity.
In this on‑demand webinar, “GLP-1 Clinical Considerations,” Truveris Clinical Director Aya Desouki, PharmD, breaks down how the latest GLP-1 clinical developments, FDA approvals, and manufacturer strategies are changing GLP‑1 coverage and pricing in 2026. She offers a detailed explanation behind the clinical considerations around oral GLP‑1s, non‑peptide small molecule therapies, multi-receptor agonists, and dose escalation risks.
Aya also outlines PBM utilization management trends, the rise of discounted cash pay channels like TrumpRx, and covers several strategic considerations employers must weigh when evaluating GLP-1 coverage.
Learning Objectives
- Understand the clinical landscape of GLP‑1 therapies: Learn about current FDA‑approved indications, emerging evidence, and how clinical differences between semaglutide, tirzepatide, and new next‑generation agents should inform benefit strategy.
- Evaluate utilization trends, risks, and cost drivers: Analyze real world utilization patterns, comparative tolerability, clinical safety considerations, along with how these translate into financial exposure and member expectations for employers.
- Assess the impact of new access and pricing models: Understand how PBM utilization management (smart edits, formulary updates), lifestyle program models (carved‑in vs carved‑out), and manufacturer direct pathways (DTE and DTC) influence cost, operational complexity, and member behavior.
- Prepare for the 2026–2027 GLP‑1 pipeline: Evaluate oral GLP‑1s (including Foundayo), non‑peptide molecules, and multi‑agonists, and learn how competitive dynamics may shape future pricing and employer coverage strategies.
Watch: GLP-1 Clinical Considerations
